Japanese Dietary Supplement: Nichi Glucan, an Immune Booster in Covid-19
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies (https://www.frontiersin.org/articles/10.3389/fimmu.2020.01548/abstract), for validation. This AFO-202 strain produced “Nichi Glucan” enhanced the immunity by increasing Natural Killer (NK) cells and anti-viral cytokines of healthy people, cancer patients and elderly, in three different studies in Japan. Encouraging outcome of earlier studies inspired us to hypothesize that, benefits of this food supplement in boosting the immunity could help during this pandemic, said Dr. Nobunao Ikewaki, a co-author.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005239/en/
Mechanisms of immune balancing potentials by Nichi Glucan from Japan, that make it worth a clinical study in Covid-19 (Graphic: Business Wire)
Analyzing the intricacies and weakness of immune system in people with comorbid conditions, making them vulnerable to severe complications when infected by SARS-COV-2, scientists say that immune system must protect the body from pathogens like viruses, but shouldn’t over-act causing hyper inflammation leading to cytokine storm ensuing in respiratory failure or complications like stroke. Nichi Glucan having been found to boost protective factors like Cytotoxic T Cells and immunoglobulins, while controlling those lead to hyper inflammation through sFas and Treg cells, balancing as immunomodulator, has potentials worth clinical studies during this global health crisis, they opine.
Unique advantages of this biological response modifier glucan are attributed to its purity, being produced as an exo-polysaccharide and its water solubility. Nichi Glucan is manufactured in a GMP factory in the banks of upstream Niyodo river in Kochi prefecture. "Pristine water of this region is a key ingredient for production, making Nichi Glucan a nature's gift," says Mr. Takashi Onaka, President, Sophy Inc., the manufacturer.
Approved as food additive in 1996 after conforming to all safety norms of Japanese standards, Nichi Glucan isn’t a drug or cure to any illness. However, in the present situation, without vaccines to prevent or drugs to tackle the Covid-19 virus or its complications, it could be tried in studies to confirm efficacy in helping the immunocompromised vulnerable population through immune enhancement, comment the authors. Further research is underway to develop newer versions with higher adhesion for improvised immune stimulation. GN Corporation, the exclusive worldwide exporter, co-applicants to a patent with Sophy Inc., are looking for country-wise partners for further research & distribution (www.nichiglucan.com).
Samuel JK Abraham
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL Strengthens European Business in the Medical Equipment Segment1.10.2020 03:30:00 EEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) has opened a new facility in JEOL (EUROPE) B.V. (Zaventem, Belgium) on October 1, 2020, aiming to strengthen the Medical Equipment business in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930006021/en/ Demo site JEOL (EUROPE) B.V. (Photo: Business Wire) This foundation, with three instruments in operation, not only offers customers the possibility of practical demonstrations and intensive service / application training, but also enables high-quality service and fast logistics from the dedicated warehouse. This new approach is based on a long-term plan that whilst keeping pace with a high standard and matured medical environment in Europe, we will also cover emerging regions such as the Middle East, Eastern Europe and Russia, where the expected growth in economy and population can lead to a steady demand for medical infrastructure. We will continue to promote over
International AI Art Competition Enters Final Round30.9.2020 19:16:00 EEST | Press release
Ten finalists have been announced for AI Artathon, the first ever international AI Art competition held in Saudi Arabia. The finalists were revealed during a livestream event to showcase artworks created by the competitors using artificial intelligence tools and techniques. The three winning teams will be announced at the Global AI Summit on 22nd October, where they will share a prize of US$133,000. The AI Artathon is an initiative of the Global AI Summit, to highlight the creative potential of humans and machines working together to create innovative artworks. Twenty teams made up of artists, graphic designers, AI experts and programmers, competed in this stage of the competition, after qualifying during a hackathon held in Riyadh in January. Over 2,000 people from over 50 countries applied to participate in the hackathon, with 300 selected for the three-day event, where teams were formed to develop initial AI art concepts. Twenty teams were selected to take part in a bootcamp, where
VALBIOTIS Publishes Its 2020 Half-Year Results and Provides an Update on Its Global Strategic Partnership with Nestlé Health Science, its strong Financial Visibility and the Promising Advances in Its Pipeline30.9.2020 18:40:00 EEST | Press release
Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its results for the first half of 2020 and provides an update on developments since the beginning of the year. Sébastien PELTIER, CEO of VALBIOTIS, commented: "Events in the first half of 2020 have transformed our outlook and helped further boost our international recognition. With the signature of the development and marketing partnership for TOTUM-63 and the launch of the final clinical phase for this Nutrition Healthcare product, entirely financed by Nestlé Health Science, we have demonstrated the soundness of our development model. We are now moving confidently towards marketing and claim submission for TOTUM-63 and, thanks to a solid financial position, we are also working to apply this same model to the rest of our Nutrition Healthcare portfolio. At the head of the
Bittrex Global to Operate Cryptocurrency Exchange From Bermuda30.9.2020 18:16:00 EEST | Press release
Bittrex Global (Bermuda) Ltd. received a full Class F Digital Assets Business Act license to operate its acclaimed cryptocurrency exchange under the supervision of the Bermuda Monetary Authority (BMA). The Bermuda-based entity will provide Bittrex Global with an additional important gateway for global accounts. From its Bermuda hub, Bittrex Global (Bermuda) will offer additional digital asset services over time subject to further approval by the BMA, such as futures. “The entire crypto industry is about looking forward,” said Bittrex Global’s CEO Tom Albright. “Working with the Bermuda Government and the BMA to be part of another regulatory community that keeps innovating is extremely exciting and is an important step in increasing crypto’s penetration at all levels of the financial industry.” Bermuda Premier David Burt added “attracting Bittrex Global to Bermuda is a significant achievement. As one of the leading global exchanges, Bittrex Global’s choice of Bermuda for expanding their
GA Telesis Plans to Deliver Renewed Confidence in Air Travel Through its New Global Distribution Agreement with Honeywell for a State-of-the-Art UV Cabin Cleaning System30.9.2020 17:50:00 EEST | Press release
In an effort to help restore confidence to the flying public, GA Telesis, LLC, has teamed with Honeywell and entered into a distribution agreement to act as a global distributor for their UV Aircraft Cabin Cleaning system. This partnership is another step in the development of GA Telesis’ Tarmac Solutions Group's ability to offer a fully comprehensive Specialized Tooling and Ground Support Equipment solution for airlines around the world. This cabin system utilizes Ultraviolet (UV) light to quickly traverse an aircraft cabin, galleys & lavatories in less than ten minutes. In addition to measures already being taken by airlines in flight like the use of cabin air exchange and HEPA filters, this new system, when properly applied, reduces certain viruses and bacteria on airplane cabin surfaces and can assist in creating a cleaner environment for passengers and crew after the airplane lands and before each flight. The UV cabin cleaning system is intended to help instill confidence to busin
Velodyne Lidar Announces Inaugural Trading on Nasdaq Global Select Market30.9.2020 16:31:00 EEST | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced shares of its common stock and warrants have begun trading on The Nasdaq Global Select Market under the ticker symbols “VLDR” (common stock) and “VLDRW” (warrants). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005166/en/ Velodyne Lidar is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies, including revolutionary sensor and software solutions. (Photo: Velodyne Lidar, Inc.) Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies, including revolutionary sensor and software solutions. These innovative technologies deliver performance, quality and flexibility to meet the needs of a wide range of industries such as autonomous vehicles and growing new markets. Currently, Velodyne serves the automotive industry with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom